Although it has been shown that the pharmacological blockade of ActRIIB ligands using a soluble receptor antagonist protects from cancer-induced cachexia in mice [4, 6], the effect of direct inhibition at the receptor level using an antibody approach has not been explored. This evidence concerns the gene ACVR2B and Cachexia.